Patient ID Emerging Tech 1
In the attached spreadsheet, we have provided ten tech companies focused on technologies related to diagnostics or patient identification, such as Glyconics, Renalytix AI, and Veracyte. Our findings can also be found below, followed by an explanation of our research methodology.
- Glyconics is producing a hand-held device to provide advance notice of acute events related to COPD. The device is powered by infrared spectrometry and will be the first of its kind in the world. The company hopes to begin trials on the product in 2019.
- The development of Glyconics's infrared spectrometer tool has been conducted in conjunction with infrared spectrometry company Spectrolytic.
2. Renalytix A
- Renalytix AI is developing an AI-driven diagnostic tool for kidney disease, which was recently granted breakthrough drug designation by the US FDA. The device is called KidneyIntelX. The company currently has an "exclusive license and collaboration agreement with the Icahn School of Medicine at Mount Sinai in New York, USA."
3. Avisa Pharma
- Avisa Pharma is currently developing BreathTest, which "is a biomarker, quantitative, point-of-care test for rapidly detecting pulmonary infections due to certain virulent pathogens without the need to collect and culture sputum or other biological samples." The device will be able to detect "a wide range of severe respiratory infections with a high degree of sensitivity."
- Avisa has partnered with Santa Fe-based company Southwest Sciences to develop the device.
- Veracyte is developing Percepta, a genomic sequencing classifier (GSC) that identifies if lung nodules found via CT scans are cancerous, identifying lung cancer patients without the need for "costly, invasive and often unnecessary procedures or to delayed treatment."
- Veracyte has partnered with Johnson & Johnson on the Percepta project.
- 4Dx is developing a technology called 4DxV, which is a "four-dimensional lung function imaging analysis that uniquely and non-invasively measures lung function in real-time within the breathing lungs." This could "provide more precise regional data" from lungs that can allow diagnosis of lung disease prior to severe symptoms developing, unlike current technologies such as spirometry.
6. Akonni Biosystems
- Akonni is currently working toward commercializing their proprietary TruArray technology, which "utilizes three-dimensional (3D) gel drop microarrays to rapidly screen a sample for hundreds of disease markers at one time, all within a microarray grid the size of your fingernail." The TruArray technology will be utilized to detect tuberculosis, in conjunction with the company's "TruDx® 3000 sample-to-answer diagnostic platform."
- Akonni has formed a commercialization partnership in China with Chinese company Righton.
7. Huawei Cloud
- Huawei Cloud, a subsidiary of Chinese company Huawei, is pioneering an AI-powered diagnostic tool for cervical cancer. The tool can identify the disease with a "true positive rate of over 99.9 percent, and a true negative rate of more than 99 percent, which is currently the highest level in the world."
- Huawei Cloud has partnered with Kingmed Diagnostics to produce the new AI technology.
- Genalyte is pioneering a blood testing system that would allow blood samples to be tested in minutes. This would allow for patient identification and diagnosis across a range of conditions. The company has an ongoing partnership with Kohsla Ventures with regard to its diagnostic platform.
- Minomic is developing a "quick, non-invasive" diagnostic tool called MiCheck to identify and diagnose individuals with prostate cancer. The test "works by measuring several protein biomarkers including a proprietary marker owned by Minomic called Glypican -1."
- Minomic has partnered with Cirrus DX, which is "a CLIA Certified 'High Complexity' Laboratory." This will allow some US clinicians to get early access to the company's novel MiCheck technology.
10. One Biomed
- One Biomed "is developing a point-of-care diagnostic platform deploying two proprietary technologies: a chemistry-based nucleic acid extraction and a silicon biophotonics dual-ring sensor."
- The company established a laboratory, along with the Agency for Science, Technology and Research, to research assays that will be utilized in conjunction with this platform. These assays will be used to diagnose a variety of infectious diseases in Asia.
To find emerging tech companies that are developing tools, apps, or other projects that will be applied in diagnostic or patient identification capacities, we conducted three research approaches. First, we conducted a wide-ranging press search, hoping to find news of such companies and/or the technologies they are developing. Second, we conducted a search of academic and medical literature, where studies regarding emerging technologies are often published. Third, we conducted a search of national and international organizations related to medicine and technology, such as the World Health Organization (WHO). Our research initially focused on Chinese companies and companies (or technologies) focused on COPD, but given the relative lack of information in these specific areas, we expanded our research globally and to other diseases.